138 related articles for article (PubMed ID: 7917762)
1. [Hypersensitivity vasculitis after thrombolytic therapy with APSAC (anisoylated plasminogen streptokinase activator complex). Presentation of a clinical case and review of the literature].
Gianni R; Benucci M; Santoro E; Nenci G; Baruffi MC; Cappelletti C
Ann Ital Med Int; 1994; 9(2):105-6. PubMed ID: 7917762
[TBL] [Abstract][Full Text] [Related]
2. Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Bucknall C; Darley C; Flax J; Vincent R; Chamberlain D
Br Heart J; 1988 Jan; 59(1):9-11. PubMed ID: 2963655
[TBL] [Abstract][Full Text] [Related]
3. Rash after treatment with anistreplase.
Burrows N; Jones RR
Br Heart J; 1990 Oct; 64(4):289-90. PubMed ID: 2223309
[TBL] [Abstract][Full Text] [Related]
4. [The adult respiratory distress syndrome as a complication of the APSAC treatment of acute myocardial infarct. Apropos a case].
García González MJ; Bosa Ojeda F; Barragán Acea A; Marrero Rodríguez F; Laynez Cerdeña I; Lara Padrón A; Lacalzada Almeida J; de Armas Trujillo D
Rev Esp Cardiol; 1993 Oct; 46(10):674-6. PubMed ID: 8235004
[TBL] [Abstract][Full Text] [Related]
5. Cholesterol embolism after intravenous anisoylated plasminogen streptokinase activator complex (APSAC).
Beutler JJ; Sulzer MA; van Stralen R
Neth J Med; 1991 Dec; 39(5-6):373-4. PubMed ID: 1803250
[No Abstract] [Full Text] [Related]
6. A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
Clin Trials Metaanal; 1993 Nov; 28(6):317-28. PubMed ID: 10150180
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous leukocytoclastic vasculitis in relation to streptokinase.
Bindels AJ; See TL; Peters WG
Neth J Med; 1992 Feb; 40(1-2):76-9. PubMed ID: 1579189
[TBL] [Abstract][Full Text] [Related]
8. Drug eruptions and isotypic antibody responses to streptokinase after infusions of anisoylated plasminogen-streptokinase complex (APSAC, anistreplase).
Dykewicz MS; McMorrow NK; Davison R; Fintel DJ; Zull CC; Rutledge JL
J Allergy Clin Immunol; 1995 May; 95(5 Pt 1):1020-8. PubMed ID: 7751498
[TBL] [Abstract][Full Text] [Related]
9. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
Brügemann J; van der Meer J; Takens BH; Hillege H; Lie KI
Br Heart J; 1990 Dec; 64(6):355-8. PubMed ID: 2271340
[TBL] [Abstract][Full Text] [Related]
10. Oesophageal dissection after thrombolytic treatment for myocardial infarction.
Jishi F; Sissons CE; Silverstone EJ; Coakley JF; Fraser F
Thorax; 1992 Oct; 47(10):835-6. PubMed ID: 1481188
[TBL] [Abstract][Full Text] [Related]
11. [Diffuse cholesterol embolism after fibrinolysis for myocardial infarction].
Pochmalicki G; Meunier P; Feldman L; Rougeau JC; Chosidow O; Wechsler J; Jan F
Arch Mal Coeur Vaiss; 1993 Feb; 86(2):263-6. PubMed ID: 8363430
[TBL] [Abstract][Full Text] [Related]
12. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
Cannas S; De Leo A; Marzari A
G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
[TBL] [Abstract][Full Text] [Related]
13. [Side effects of thrombolytic therapy in patients with myocardial infarction].
Agostoni A; Gardinali M
Cardiologia; 1995 Dec; 40(12):899-908. PubMed ID: 8901040
[No Abstract] [Full Text] [Related]
14. Adult respiratory distress syndrome following thrombolytic therapy with APSAC for acute myocardial infarction.
Le SP; Chatterjee K; Wolfe CL
Am Heart J; 1992 May; 123(5):1368-9. PubMed ID: 1575153
[No Abstract] [Full Text] [Related]
15. Lymphocytic angiitis following streptokinase therapy.
Sorber WA; Herbst V
Cutis; 1988 Jul; 42(1):57-8. PubMed ID: 3060319
[TBL] [Abstract][Full Text] [Related]
16. [Thrombolytic therapy in acute myocardial infarct--is it being used to the fullest?].
Carôla B; Calçada-Correia L; Pedro PG; Conduto R; Dionísio I; Fiuza M; Dias E; Vaz Carneiro A; Amador MG; de Pádua F; Lopes MG
Rev Port Cardiol; 1996 Dec; 15(12):867-76, 863. PubMed ID: 9052962
[TBL] [Abstract][Full Text] [Related]
17. Clinical risks of thrombolytic therapy.
Califf RM; Fortin DF; Tenaglia AN; Sane DC
Am J Cardiol; 1992 Jan; 69(2):12A-20A. PubMed ID: 1729875
[TBL] [Abstract][Full Text] [Related]
18. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
Bell WR
Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic therapy for acute myocardial infarction. Are inclusion criteria too stringent?
Handlin LR; Vacek JL
Postgrad Med; 1994 Mar; 95(4):77-82. PubMed ID: 8121861
[TBL] [Abstract][Full Text] [Related]
20. [Cholesterol embolization after intravenous streptokinase therapy in acute myocardial infarction].
Bucher A; Roald B
Tidsskr Nor Laegeforen; 1993 Jun; 113(15):1844-5. PubMed ID: 8322322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
